What Is the Most Affordable Weight Loss Drug?

The direct answer, and why it is incomplete on its own

If the question is only "which prescription weight loss drug has the lowest cash price," the answer is generic phentermine, a Schedule IV sympathomimetic amine approved by the FDA for short-term obesity management. It is not a GLP-1 receptor agonist, it is not tirzepatide, and it works through a different mechanism (appetite suppression via norepinephrine release) than semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), which are injectable incretin-based drugs.

The useful question for most readers is not which drug is cheapest per month, but which drug is cheapest per unit of durable weight loss for their specific health profile, insurance status, and time horizon. A drug priced at $20 a month that a patient stops after 12 weeks and regains weight from is not obviously more affordable, in a total-cost sense, than a drug priced at $150 to $400 a month that is used consistently for a year with sustained loss. Neither is automatically the right answer for a given reader; the tradeoff depends on comorbidities, how much weight loss is medically needed, and what a person can actually keep paying month after month.

The price tiers you are actually choosing between

Generic single-agent drugs. Phentermine, metformin, and generic bupropion or topiramate as standalone drugs sit at the low end, commonly cited in the low tens of dollars per month at major discount pharmacy programs.

Generic combination drugs. Phentermine/topiramate ER (brand Qsymia) and naltrexone/bupropion ER (brand Contrave) now have generic versions on the US market. Reported pricing for these generics is generally in the roughly $75 to $200 per month range, well below brand pricing for the same combinations.

Compounded GLP-1 peptides. During an FDA-declared drug shortage, compounding pharmacies registered under Section 503A or outsourcing facilities registered under Section 503B may legally prepare copies of an FDA-approved drug. Telehealth programs have advertised compounded semaglutide in the $150 to $400 per month range. This is not a stable price tier: it depends entirely on the current shortage determination, which the FDA can and has changed. The FDA's compounding guidance explains the legal framework for 503A and 503B compounding during shortages (FDA compounding Q&A). Readers should verify the current shortage status and the compounding pharmacy's registration type with their prescriber before assuming this option is available or legal at the time they read this.

Brand-name GLP-1 receptor agonists. Wegovy and Zepbound carry list prices above $1,000 per month. Manufacturer savings programs can lower this substantially for commercially insured, eligible patients, but these programs generally exclude people on Medicare or Medicaid, and coverage rules change. Any specific savings-card figure should be confirmed on the manufacturer's current program page before a patient relies on it, since these terms move over time.

Why insurance coverage, not drug price, usually decides your actual cost

Employer health plans in the US are not required to cover obesity drugs the way they are required to cover many other chronic disease treatments. Coverage for GLP-1s specifically for obesity (as opposed to type 2 diabetes) has historically lagged coverage for diabetes indications, and industry survey data has repeatedly described coverage for obesity-indicated GLP-1s as covering a minority of large employer plans. Readers should treat any specific coverage percentage as time-sensitive and confirm current numbers with their own plan documents rather than relying on a cited statistic, since payer policy changes faster than published estimates.

If your plan does not cover weight-loss drugs, your real choice set narrows to cash-pay generics, OTC orlistat, and whatever compounded or discounted option is legally available at the time, which shifts the practical answer toward the lower-cost tiers described above.

Generic phentermine: lowest price, narrowest approved use

Phentermine suppresses appetite through central norepinephrine release and has been FDA-approved since 1959 for short-term obesity management, generally understood as up to about 12 weeks. It is a Schedule IV controlled substance requiring a prescription. Published trial evidence on phentermine monotherapy generally describes a modest weight loss advantage over placebo, on the order of a few kilograms over 12 weeks, not the double-digit percentage losses seen with GLP-1 drugs. Exact figures from any specific trial should be checked against the primary publication before being used in patient counseling material, since the underlying citation for a precise number was not independently verifiable for this draft.

Phentermine combined with topiramate ER (Qsymia and its generics) produces larger average weight loss than phentermine alone in published trial data, though exact percentage figures again require verification against the primary trial report rather than being repeated from a secondary summary. Women of childbearing potential prescribed phentermine/topiramate ER must go through the drug's FDA-mandated Risk Evaluation and Mitigation Strategy because topiramate is a known teratogen; the current REMS program is described on the FDA's REMS page (FDA REMS details).

Phentermine is generally avoided in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, or a history of substance use disorder, and it is contraindicated in pregnancy. It is approved for adults; it is not approved for use in children.

Metformin: the cheapest option, with real but modest evidence

Metformin does not have an FDA-approved weight loss indication. It is approved for type 2 diabetes, and clinicians prescribe it off-label for weight management in patients with insulin resistance, prediabetes, or polycystic ovary syndrome. This is an established off-label use in clinical practice, not an FDA-approved indication, and that distinction matters for how much weight loss a patient should realistically expect. The magnitude of weight loss with metformin in prediabetes populations is generally described in the literature as modest, clearly smaller than what lifestyle intervention alone or GLP-1 drugs produce, even though the metabolic and cardiovascular rationale for using it in insulin-resistant patients is well established. At its typical generic cash price, metformin remains one of the least expensive drugs a clinician might reach for in an appropriate patient, even though weight loss is a secondary rather than primary benefit.

Metformin requires dose adjustment or avoidance at significantly reduced kidney function, and this should be checked against a patient's renal function before prescribing.

Naltrexone/bupropion (Contrave and its generics): a middle tier

Brand Contrave carries a high list price; a generic naltrexone/bupropion ER entered the US market and is typically priced well below the brand, placing it between phentermine and branded GLP-1s. The combination targets both reward-related eating behavior (through naltrexone's opioid receptor blockade) and appetite regulation (through bupropion's effect on dopamine and norepinephrine reuptake). Bupropion carries an FDA boxed warning regarding suicidality risk in patients under 25 and is contraindicated in patients with seizure disorders; naltrexone cannot be started in patients currently using full-agonist opioids without a supervised discontinuation process first (Contrave prescribing information).

Orlistat: the only OTC option, and the most gut-limited mechanism

Orlistat 60 mg (Alli) is sold over the counter; the prescription-strength 120 mg version (formerly Xenical, now generic) requires a prescription. Orlistat works by inhibiting pancreatic lipase and blocking a portion of dietary fat absorption in the gut, which means it has minimal systemic absorption compared with appetite-suppressant or incretin-based drugs (orlistat prescribing information). Its gastrointestinal side effects, including oily stools and fecal urgency, are common and drive high real-world discontinuation rates even in patients for whom systemic drug interactions are a concern. Fat-soluble vitamin depletion is a known risk with sustained use.

Compounded semaglutide: the affordable GLP-1 middle ground, with a moving regulatory floor

This is the category most likely to change between when this article is written and when it is read. Compounded semaglutide became widely available through telehealth platforms while Ozempic and Wegovy were on the FDA's drug shortage list, because federal law permits 503A and 503B compounding of an FDA-approved drug's active ingredient during a declared shortage. Once the FDA removes a drug from the shortage list, the legal basis for broad compounding narrows, and 503A pharmacies in particular are expected to wind down production on a defined timeline, while 503B outsourcing facilities may operate under different rules.

Because this status can change quickly, any specific date or wind-down deadline cited for semaglutide compounding should be verified directly against the FDA's current drug shortage database and compounding guidance at the time a reader is deciding, rather than taken from this article as a fixed fact (FDA compounding Q&A).

There is a separate scientific caveat beyond legality. Compounded formulations sometimes use a different salt or base form of semaglutide than the FDA-approved product, and the pharmacokinetic equivalence of these forms has not been established in the same large trials that support the approved drug. A reasonable question to ask a prescriber or pharmacy is whether the compounded product uses the same active form as the approved drug, and whether the pharmacy is 503A or 503B registered.

Brand GLP-1s: the largest published effect sizes, at the highest list price

Semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) are the two agents in this class with FDA approval specifically for chronic weight management, distinct from the diabetes-approved formulations of the same molecules (Ozempic, Mounjaro). Published randomized trials for both drugs report substantially larger average weight loss than older agents, generally in the double digits as a percentage of starting body weight over roughly a year of treatment. Exact percentage figures for any specific trial should be checked against the primary NEJM publication before being repeated in patient-facing material, since this draft could not independently verify a specific citation against a matched trial in the sources available.

Manufacturer savings programs exist for both drugs and can substantially lower monthly out-of-pocket cost for eligible, commercially insured patients, but these programs typically exclude Medicare and Medicaid beneficiaries and have specific eligibility rules that change. A reader relying on a savings-card price should confirm current terms directly on the manufacturer's program page rather than a fixed number in an article, since these prices are volatile and dated information becomes wrong quickly.

What about liraglutide (Saxenda)?

Saxenda (liraglutide 3.0 mg) was the first GLP-1 approved specifically for chronic weight management. It requires daily rather than weekly injections and generally produces smaller average weight loss in published trials than semaglutide 2.4 mg. Its list price is comparable to Wegovy's. Given once-weekly semaglutide's larger published effect size, liraglutide is not usually the first choice today unless a specific insurance formulary favors it.

What is established, what is plausible, and what is not established

Established: Generic phentermine has the lowest typical cash price among prescription weight loss drugs in the US. Brand GLP-1 drugs (Wegovy, Zepbound) have list prices far above generic older agents. FDA-approved indications differ meaningfully across this drug class: some agents (phentermine, orlistat, liraglutide, semaglutide 2.4 mg, tirzepatide) are approved specifically for weight management, while metformin is approved only for diabetes and used off-label for weight-related indications.

Plausible but requiring verification for any specific number: The precise magnitude of weight loss reported in individual trials for phentermine, phentermine/topiramate, naltrexone/bupropion, and metformin. The exact percentage of insurance plans currently covering GLP-1s for obesity. The exact manufacturing cost of semaglutide relative to its list price. These directional claims are consistent with what is generally known about this drug class, but a specific cited number should not be treated as verified without checking the primary trial report or current payer data.

Not established: That compounded semaglutide is pharmacokinetically equivalent to the FDA-approved product. That any specific compounded semaglutide program will remain legally available at a given price by the time a reader reads this, given that FDA shortage determinations and compounding rules are actively changing.

A decision framework for choosing among these options

The following is an original synthesis for this article, not a clinical protocol. It is meant to organize the tradeoffs above into a starting conversation with a prescriber, not to replace individualized medical advice.

The recurring pattern in this table is that the lowest-price option in almost every row carries either a narrower approved use, a smaller expected effect, or a monitoring requirement that the higher-price option does not. Affordability should be evaluated against what you actually need the drug to do, not against the sticker price alone.

Questions worth asking your prescriber about cost

1. Is there a generic version of what you are recommending, and how does its expected effect compare with the brand?
2. Does my insurance formulary cover any weight-loss medication, and at what tier or prior-authorization requirement?
3. Is there a manufacturer savings program I might qualify for, and does it apply to my type of coverage?
4. If compounded semaglutide comes up, can you confirm the pharmacy's 503A or 503B status and whether it is currently permitted under the FDA's current shortage determination?
5. Given my other conditions, is a lower-cost older drug a reasonable place to start, or does my BMI or comorbidity profile make a GLP-1 drug the more appropriate first choice regardless of price?

When to seek urgent care rather than adjusting a weight-loss drug on your own

Severe abdominal pain, persistent vomiting, signs of an allergic reaction, chest pain, or suicidal thoughts while on any of these medications warrant urgent medical attention rather than waiting for a routine follow-up. Do not stop or change a prescribed dose based on cost concerns without talking to the prescribing clinician, since some of these drugs (including bupropion-containing combinations) should not be stopped abruptly.